Ongoing research into AI agent framework security identified an exploit chain in AutoGen Studio (AutoGen’s open-source prototyping user interface) that allows untrusted web content rendered by a ...

Eclipse Open VSX has reached 1.0.0, highlighting its role as a vendor-neutral registry for VS Code-compatible extensions.

Infragistics Ultimate 26.1 introduces the Ignite UI Enterprise MCP toolchain for AI-assisted app development across Angular, React, Web Components and Blazor.

Ironsmith is a free AI Mac app builder that turns plain-language requests into native macOS utilities, with local and cloud model options for creating small personal tools.

Gemini is getting a bit more useful today. Google has begun rolling out an update that gives its chatbot the ability to generate files directly from the prompt bar. To use the new feature, all you ...

You can now ask the Gemini app to directly generate “downloadable and ready-to-share files.” Google wants you to “quickly move from a brainstorm to a complete ...

OpenAI’s decision last week to shut down Sora, its AI video-generation tool, just six months after releasing it to the public, raised immediate suspicions. The app had invited users to upload their ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...